The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Targeting Hsp90: small-molecule inhibitors and their clinical development
Open accessAbstract
The Hsp90 multichaperone complex has important roles in the development and progression of malignant transformation. Several small-molecule inhibitors of Hsp90 of diverse chemotypes have shown potent antitumor activity in a wide-range of malignancies, and are currently in clinical or late-stage preclinical investigation. This review intends to update the reader on advances made over the past two years in the clinical development of Hsp90 inhibitors in advanced cancers. It will refer to the two 17-AAG formulations, tanespimycin and IPI-504, and to synthetic small molecules, among which are the purine-scaffold Hsp90 inhibitor CNF2024/BIIB021, the isoxazole derivative VER-52296/NVP-AUY922, and the carbazol-4-one benzamide derivative SNX-5422, and will present our current knowledge on their clinical performance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
Modi, S., Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
Development and application of Hsp90 inhibitors
Solit, D. B., & Chiosis, G. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.007 · Cited by 251
Self-citationSydor, J. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Hudak, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608372103 · Cited by 231
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Whitesell, L., Bagatell, R., & Falsey, R. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481787 · Cited by 203
Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A., & Rosen, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16580 · Cited by 189
Citri, A., Kochupurakkal, B. S., & Yarden, Y. (2004) · Cell Cycle · doi:10.4161/cc.3.1.607 · Cited by 174
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
Rodina, A., Vilenchik, M., Moulick, K., Aguirre, J., Kim, J., Chiang, A., Litz, J., Clement, C. C., Kang, Y., She, Y., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.10 · Cited by 156
Self-citationDiscovery and Development of Pyrazole-Scaffold Hsp90 Inhibitors
McDonald, E., Jones, K., Brough, P. A., Drysdale, M., & Workman, P. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812086 · Cited by 143
Bonvini, P., Gastaldi, T., Falini, B., & Rosolen, A. (2002) · PubMed · Cited by 130
Castro, J. E., Prada, C. E., Loria, O., Kamal, A., Chen, L., Burrows, F. J., & Kipps, T. J. (2005) · Blood · doi:10.1182/blood-2005-03-1099 · Cited by 127
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis, G., Lopes, E. C., & Solit, D. B. (2006) · PubMed · Cited by 79
Self-citationBanerji, U., Affolter, A., Judson, I. R., Marais, R., & Workman, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0145 · Cited by 76
FLT3 inhibition in acute myeloid leukaemia
Knapper, S. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06700.x · Cited by 74
Peng, C., Li, D., & Li, S. (2007) · Cell Cycle · doi:10.4161/cc.6.18.4722 · Cited by 44
Discovery and development of purine-scaffold Hsp90 inhibitors
Chiosis, G., Kang, Y., & Sun, W. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.99 · Cited by 32
Self-citationBryson, J. C., Infante, J. R., Ramanathan, R. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14613 · Cited by 20
Heat Shock Protein 90: The Cancer Chaperone
Neckers, L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6401-2_12 · Cited by 18
Cited by
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
Protein Folding in the Cytoplasm and the Heat Shock Response
Vabulas, R. M., Raychaudhuri, S., Hayer-Hartl, M., & Hartl, F. U. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004390 · Cited by 428
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413
Metadata
- Authors
- Taldone, T., Gozman, A., Maharaj, R., & Chiosis, G.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 8
- Issue
- 4
- Pages
- 370-374
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W1970700441
- Cited by
- 284
- References
- 22
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.